Handelsbanken Fonder AB Lowers Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Handelsbanken Fonder AB lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 55.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 74,898 shares of the biopharmaceutical company's stock after selling 94,845 shares during the period. Handelsbanken Fonder AB owned approximately 0.06% of Alnylam Pharmaceuticals worth $14,336,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Quent Capital LLC boosted its holdings in Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 123 shares in the last quarter. Anchor Investment Management LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $38,000. Lindbrook Capital LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 37.2% in the fourth quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 100 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 52.4% in the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company's stock valued at $160,000 after purchasing an additional 311 shares in the last quarter. Finally, Avitas Wealth Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $204,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Morgan Stanley reduced their price target on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 13th. The Goldman Sachs Group lowered Alnylam Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the company from $230.00 to $173.00 in a research report on Friday, February 16th. Needham & Company LLC reaffirmed a "buy" rating and issued a $200.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. JPMorgan Chase & Co. raised their target price on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a "neutral" rating in a research report on Thursday, February 1st. Finally, Wells Fargo & Company cut their price objective on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an "equal weight" rating on the stock in a report on Friday, February 16th. Nine investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $216.12.

Alnylam Pharmaceuticals Stock Down 1.6 %

Shares of Alnylam Pharmaceuticals stock traded down $2.27 during midday trading on Wednesday, hitting $143.80. The company's stock had a trading volume of 395,369 shares, compared to its average volume of 783,886. The firm has a market capitalization of $18.11 billion, a P/E ratio of -40.39 and a beta of 0.39. The stock has a 50-day simple moving average of $150.77 and a 200-day simple moving average of $166.28. Alnylam Pharmaceuticals, Inc. has a 1-year low of $143.50 and a 1-year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, topping analysts' consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. During the same period in the prior year, the firm earned ($1.68) EPS. Alnylam Pharmaceuticals's quarterly revenue was up 31.2% on a year-over-year basis. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.